Subclinical Hypothyroidism and Cardiovascular Disease

Subclinical hypothyroidism (SCH) is a common disorder that is characterized by elevated thyroid-stimulating hormone levels in conjunction with free thyroxine concentrations within the normal reference range. Thyroid hormones are known to affect the heart and vasculature and, as a result, the impact...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Endocrinology and metabolism (Seoul) 2015-09, Vol.30 (3), p.246
Hauptverfasser: Sung Hwan Suh, Duk Kyu Kim
Format: Artikel
Sprache:kor
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 3
container_start_page 246
container_title Endocrinology and metabolism (Seoul)
container_volume 30
creator Sung Hwan Suh
Duk Kyu Kim
description Subclinical hypothyroidism (SCH) is a common disorder that is characterized by elevated thyroid-stimulating hormone levels in conjunction with free thyroxine concentrations within the normal reference range. Thyroid hormones are known to affect the heart and vasculature and, as a result, the impact of SCH on the cardiovascular (CV) system has recently become an important topic of research. Strong evidence points to a link between SCH and CV risk factors such as alterations in blood pressure, lipid levels, and atherosclerosis. Additionally, accumulating evidence indicates that SCH is associated with metabolic syndrome and heart failure. The present review proposes that SCH may be a potentially modifiable risk factor of CV disease and mortality. However, large-scale clinical trials with appropriate power investigating the risks and benefits of SCH treatment are required to determine whether these benefits can be achieved with levothyroxine therapy.
format Article
fullrecord <record><control><sourceid>kiss</sourceid><recordid>TN_cdi_kiss_primary_3356908</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><kiss_id>3356908</kiss_id><sourcerecordid>3356908</sourcerecordid><originalsourceid>FETCH-kiss_primary_33569083</originalsourceid><addsrcrecordid>eNpjYeA0MrA01jW1NIvgYOAtLs4yAAILCxNDI0NOBtPg0qTknMy8zOTEHAWPyoL8kozKovzMlMziXIXEvBQF58SilMz8ssTi5NKcxCIFl8zi1MTiVB4G1rTEnOJUXijNzSDt5hri7KGbnVlcHF9QlJmbWFQZb2xsamZpYGGMXxYAm94wDg</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Subclinical Hypothyroidism and Cardiovascular Disease</title><source>KoreaMed Synapse</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>KoreaMed Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Sung Hwan Suh ; Duk Kyu Kim</creator><creatorcontrib>Sung Hwan Suh ; Duk Kyu Kim</creatorcontrib><description>Subclinical hypothyroidism (SCH) is a common disorder that is characterized by elevated thyroid-stimulating hormone levels in conjunction with free thyroxine concentrations within the normal reference range. Thyroid hormones are known to affect the heart and vasculature and, as a result, the impact of SCH on the cardiovascular (CV) system has recently become an important topic of research. Strong evidence points to a link between SCH and CV risk factors such as alterations in blood pressure, lipid levels, and atherosclerosis. Additionally, accumulating evidence indicates that SCH is associated with metabolic syndrome and heart failure. The present review proposes that SCH may be a potentially modifiable risk factor of CV disease and mortality. However, large-scale clinical trials with appropriate power investigating the risks and benefits of SCH treatment are required to determine whether these benefits can be achieved with levothyroxine therapy.</description><identifier>ISSN: 2093-596X</identifier><language>kor</language><publisher>대한내분비학회</publisher><subject>Cardiovascular diseases ; Subclinical hypothyroidism</subject><ispartof>Endocrinology and metabolism (Seoul), 2015-09, Vol.30 (3), p.246</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Sung Hwan Suh</creatorcontrib><creatorcontrib>Duk Kyu Kim</creatorcontrib><title>Subclinical Hypothyroidism and Cardiovascular Disease</title><title>Endocrinology and metabolism (Seoul)</title><addtitle>Endocrinology and Metabolism</addtitle><description>Subclinical hypothyroidism (SCH) is a common disorder that is characterized by elevated thyroid-stimulating hormone levels in conjunction with free thyroxine concentrations within the normal reference range. Thyroid hormones are known to affect the heart and vasculature and, as a result, the impact of SCH on the cardiovascular (CV) system has recently become an important topic of research. Strong evidence points to a link between SCH and CV risk factors such as alterations in blood pressure, lipid levels, and atherosclerosis. Additionally, accumulating evidence indicates that SCH is associated with metabolic syndrome and heart failure. The present review proposes that SCH may be a potentially modifiable risk factor of CV disease and mortality. However, large-scale clinical trials with appropriate power investigating the risks and benefits of SCH treatment are required to determine whether these benefits can be achieved with levothyroxine therapy.</description><subject>Cardiovascular diseases</subject><subject>Subclinical hypothyroidism</subject><issn>2093-596X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpjYeA0MrA01jW1NIvgYOAtLs4yAAILCxNDI0NOBtPg0qTknMy8zOTEHAWPyoL8kozKovzMlMziXIXEvBQF58SilMz8ssTi5NKcxCIFl8zi1MTiVB4G1rTEnOJUXijNzSDt5hri7KGbnVlcHF9QlJmbWFQZb2xsamZpYGGMXxYAm94wDg</recordid><startdate>20150930</startdate><enddate>20150930</enddate><creator>Sung Hwan Suh</creator><creator>Duk Kyu Kim</creator><general>대한내분비학회</general><scope>HZB</scope><scope>Q5X</scope></search><sort><creationdate>20150930</creationdate><title>Subclinical Hypothyroidism and Cardiovascular Disease</title><author>Sung Hwan Suh ; Duk Kyu Kim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kiss_primary_33569083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>kor</language><creationdate>2015</creationdate><topic>Cardiovascular diseases</topic><topic>Subclinical hypothyroidism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sung Hwan Suh</creatorcontrib><creatorcontrib>Duk Kyu Kim</creatorcontrib><collection>Korea Information Science Society (KISS)</collection><collection>Korean Studies Information Service System (KISS) B-Type</collection><jtitle>Endocrinology and metabolism (Seoul)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sung Hwan Suh</au><au>Duk Kyu Kim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Subclinical Hypothyroidism and Cardiovascular Disease</atitle><jtitle>Endocrinology and metabolism (Seoul)</jtitle><addtitle>Endocrinology and Metabolism</addtitle><date>2015-09-30</date><risdate>2015</risdate><volume>30</volume><issue>3</issue><spage>246</spage><pages>246-</pages><issn>2093-596X</issn><abstract>Subclinical hypothyroidism (SCH) is a common disorder that is characterized by elevated thyroid-stimulating hormone levels in conjunction with free thyroxine concentrations within the normal reference range. Thyroid hormones are known to affect the heart and vasculature and, as a result, the impact of SCH on the cardiovascular (CV) system has recently become an important topic of research. Strong evidence points to a link between SCH and CV risk factors such as alterations in blood pressure, lipid levels, and atherosclerosis. Additionally, accumulating evidence indicates that SCH is associated with metabolic syndrome and heart failure. The present review proposes that SCH may be a potentially modifiable risk factor of CV disease and mortality. However, large-scale clinical trials with appropriate power investigating the risks and benefits of SCH treatment are required to determine whether these benefits can be achieved with levothyroxine therapy.</abstract><pub>대한내분비학회</pub><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2093-596X
ispartof Endocrinology and metabolism (Seoul), 2015-09, Vol.30 (3), p.246
issn 2093-596X
language kor
recordid cdi_kiss_primary_3356908
source KoreaMed Synapse; DOAJ Directory of Open Access Journals; PubMed Central Open Access; KoreaMed Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Cardiovascular diseases
Subclinical hypothyroidism
title Subclinical Hypothyroidism and Cardiovascular Disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T20%3A32%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kiss&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Subclinical%20Hypothyroidism%20and%20Cardiovascular%20Disease&rft.jtitle=Endocrinology%20and%20metabolism%20(Seoul)&rft.au=Sung%20Hwan%20Suh&rft.date=2015-09-30&rft.volume=30&rft.issue=3&rft.spage=246&rft.pages=246-&rft.issn=2093-596X&rft_id=info:doi/&rft_dat=%3Ckiss%3E3356908%3C/kiss%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_kiss_id=3356908&rfr_iscdi=true